Open-label, randomised trial to evaluate the efficacy and safety of MOR00208 with Bendamustine (BEN) versus Rituximab (RTX) with BEN in adult patients with R-R DLBCL (#628)
Laufzeit: 01.01.2017 - 31.12.2040
imported
Kurzfassung
A phase II/III, randomised, multicenter study of MOR00208 with Bendamustine versus Rituximab with Bendamustine in patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R-R DLBCL) who are not eligible for High-Dose Chemotherapy (HDC) and Autologous Stem-Cell Transplantation (ASCT)
